Document Detail

RNASEL germline variants are associated with pancreatic cancer.
MedLine Citation:
PMID:  15981205     Owner:  NLM     Status:  MEDLINE    
The RNASEL (encoding ribonuclease L) gene Glu265X mutation has been implicated in familial prostate cancer, and an association between the RNASEL Arg462Gln variant and sporadic and familial prostate cancer, has also been suggested. Because prostate cancer occurs in some familial pancreatic cancer families, we evaluated the role of the RNASEL gene variants Glu265X and Arg462Gln in the etiology of pancreatic cancer. Exon 2 of the RNASEL gene was directly sequenced in the germline of 36 familial and 75 sporadic pancreatic cancer patients and in 108 controls. The Glu265X mutation was identified in one (2.8%) familial and one (1.3%) sporadic pancreatic cancer case, but not in any of the controls. Arg462Gln variants were identified in 61 (56%) controls and in 55 (73%) sporadic pancreatic cancer cases with 8 (7%) and 12 (16%) homozygotes, respectively (p = 0.009). For homozygous carriers the increased risk for pancreatic cancer was 3.5 (odds ratio [OR] = 3.53, 95% confidence interval [CI] = 1.11-11.46, p = 0.03). The population attributable fraction (PAF) was 38.7% (95% CI = 0.08-0.80). In familial pancreatic cancer no association between Arg462Gln genotypes and pancreatic cancer risk was evident. In sporadic pancreatic cancer there were no significant differences between Arg462Gln genotypes regarding clinical characteristics. In familial pancreatic cancer, however, patients with Arg462Gln variants had more aggressive tumors with more high grade cancers (OR = 15.40, p = 0.009) and more distant metastases (OR = 7.00, p = 0.04) than patients with the wild-type genotype. Our results suggest that RNASEL variants Glu265X and Arg462Gln may contribute to the tumorigenesis of sporadic and familial pancreatic cancer, which has to be proven in large scale studies.
Detlef K Bartsch; Volker Fendrich; Emily P Slater; Mercedes Sina-Frey; Harald Rieder; William Greenhalf; Brunhilde Chaloupka; Stephan A Hahn; John P Neoptolemos; Ralf Kress
Related Documents :
20423995 - Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implic...
8714225 - Brachytherapy for pancreatic cancer: a review.
20302205 - Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report.
22030255 - Targeting p53 as a therapeutic strategy in sensitizing trail-induced apoptosis in cance...
22020495 - Aspects of esophageal atresia in a population-based setting: incidence, mortality, and ...
16761895 - Determinants of prostate cancer screening in a sample of african american military serv...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  117     ISSN:  0020-7136     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-10-18     Completed Date:  2006-01-23     Revised Date:  2011-06-17    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  718-22     Citation Subset:  IM    
Copyright Information:
Copyright 2005 Wiley-Liss, Inc
Department of Surgery, Philipps-University, Marburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Base Sequence
DNA Primers
Endoribonucleases / genetics*
Germ-Line Mutation*
Middle Aged
Pancreatic Neoplasms / genetics*
Reg. No./Substance:
0/DNA Primers; EC 3.1.-/Endoribonucleases; EC 3.1.26.-/2-5A-dependent ribonuclease

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregul...
Next Document:  Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prosta...